Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 8;217(2):e20191009. doi: 10.1084/jem.20191009

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Tanaka et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 1. — Reduction of T reg cells, particularly eT reg cells, by imatinib treatment. (A) Representative CD45RA and FoxP3 staining of CD4⁺ T cells in the blood from a healthy donor (HD) and CML patients in CMR or non-CMR. (B) Frequencies of total FoxP3⁺ T cells and each subset (Fr. I, II, III, IV, and V) among CD4⁺ T cells from PBMCs of healthy donors (n = 15) and CML patients in CMR (n = 51) or non-CMR (n = 42). Data are pooled from more than two independent experiments. (C) Correlation evaluated by ROC curves between CMR achievement and decrease of total and each subset (Fr. I, II, and III) of FoxP3⁺ T cells from CML patients’ PBMCs in B. Horizontal lines in B indicate medians. Statistical significance was assessed by Mann-Whitney U test in B.